• Samsung Biologics issued a corrected filing on its rights offering decision, reflecting a revised first indicative offer price.
• Indicative offer price for common shares cut to KRW 1,174,000 from KRW 1,322,000; final price still due Nov. 4.
• Proceeds earmarked solely for acquisition of other companies’ securities, now set at KRW 2.66 trillion; prior split allocation removed.
• Offering size unchanged at 2,270,000 common shares via shareholder allocation with rump shares offered to the public.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261001000449), on October 01, 2026, and is solely responsible for the information contained therein.